<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5AFDC37E-9DE3-442D-BCA9-E61BB4317AA6"><gtr:id>5AFDC37E-9DE3-442D-BCA9-E61BB4317AA6</gtr:id><gtr:name>Centre for Process Innovation (CPI)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>The Roslin Institute</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5AFDC37E-9DE3-442D-BCA9-E61BB4317AA6"><gtr:id>5AFDC37E-9DE3-442D-BCA9-E61BB4317AA6</gtr:id><gtr:name>Centre for Process Innovation (CPI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8C461B7D-12CA-49CE-8D96-46F91D095EAE"><gtr:id>8C461B7D-12CA-49CE-8D96-46F91D095EAE</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Christopher</gtr:otherNames><gtr:surname>Gill</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C51E1DF5-C608-4BDD-9296-5F6428F84787"><gtr:id>C51E1DF5-C608-4BDD-9296-5F6428F84787</gtr:id><gtr:firstName>Helen</gtr:firstName><gtr:surname>Sang</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/04500FFE-1F94-4408-9BD3-DF03F442C094"><gtr:id>04500FFE-1F94-4408-9BD3-DF03F442C094</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Arthur</gtr:otherNames><gtr:surname>Hume</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FM021920%2F1"><gtr:id>B64843F8-FCF9-4CF1-8D7E-2B59D5055628</gtr:id><gtr:title>Clinical applications of recombinant CSF1-Fc produced in the eggs of transgenic hens in veterinary and human medicine</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/M021920/1</gtr:grantReference><gtr:abstractText>Biologics are pharmaceutical proteins very effective at treating a number of previously intractable medical conditions. They are an increasing proportion of the human drugs market, but widespread use in veterinary settings has been prevented by high production cost. Replacing the expensive mammalian cell culture systems with transgenic chickens has significant potential to reduce this cost. With our system, hens can produce protein of consistent quantity and activity over their entire laying lives, and purification is performed using standard techniques. Here we propose to take forward our recent success producing active pig CSF1-Fc in transgenic hens' eggs by purifying large quantities and testing in potential applications. We will scale up purification, perform full quality control, test in pig models of human disease, and provide material to other experts for evaluation. We will also produce a new transgenic line expressing dog CSF1-Fc for future studies in veterinary medicine.</gtr:abstractText><gtr:fund><gtr:end>2017-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2015-05-11</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>554484</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centre for Process Innovation (CPI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Purification technologies</gtr:description><gtr:id>72F39C1E-72D4-4428-9A30-BB78D267983A</gtr:id><gtr:impact>Outcomes will be described in publications in 2017.</gtr:impact><gtr:outcomeId>58c00b783eb0e4.10260458-1</gtr:outcomeId><gtr:partnerContribution>Working with the CPI we have developed a scalable purification process, yielding high quality, pure and biologically active recombinant protein.</gtr:partnerContribution><gtr:piContribution>We developed lab scale purification of recombinant proteins from the eggs of transgenic hens.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We have shown that recombinant protein synthesised by GM hens as a component of egg white can be purified using technology that is scalable for commercial production. Purified protein is of high quality and purity and of predicted biological activity.</gtr:description><gtr:exploitationPathways>The technologies developed may be used as a platform technology for producing biologics for the reagents and animal health markets. We are actively seeking additional partners and funding to advance this.</gtr:exploitationPathways><gtr:id>AAAECD38-734F-4A88-AE41-88B1C2747FC4</gtr:id><gtr:outcomeId>56d74baf61bbd2.58876052</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BB/M021920/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>